Discover the data behind how legacy PBMs make millions off of supposedly “low-cost” biosimilars—and how businesses and members end up footing the bill.

Learn how legacy PBMs intentionally influence drug mix for their own gain and why active drug mix management, not just chasing discounts, is key to massive employer savings.

Explore our key takeaways from the SmithRx BAM Summit and discover why transparency is the key to a better, brighter future for pharmacy benefits.

Walk through a comparsion of different plan options to understand why a self-insured, carve-out model is the best approach.

Discover how legacy Pharmacy Benefits Managers are failing the pharmacy industry and why modern PBMs are the future of pharmacy benefits.

Discover what the pillars of a modern PBM are and the effect they have on the pharmacy benefits experience.

Legacy PBMs are pushing community pharmacies out of business. Discover why your local pharmacy is at risk and how transparent PBM solutions can help them survive.

Hear how SmithRx rebuilt the PBM model for full transparency—no spread pricing, no rebate games, just clear costs and aligned incentives.

The FTC’s latest report exposes PBM pricing tactics that SmithRx has long warned about. Employers can act now with a transparent PBM model.

Let's take a look at the top 4 PBM trends to watch in 2025, from transparency to value-based contracts, and how they impact healthcare costs.

SmithRx's first Broker Account Manager Summit in Dallas united industry professionals for intensive learning and networking.

SmithRx CEO Jake Frenz addresses recent news coverage scrutinizing traditional PBM practices. He highlights how SmithRx's transparent, client-focused approach differs from legacy PBMs.

A recent Wall Street Journal article reveals unexpected cost increases from mail-order pharmacies. Our blog highlights key issues for brokers and plan sponsors, including rising drug costs and choosing a conflict-free PBM.

Discover why drug prices keep rising in America. Learn how Pharmacy Benefit Managers (PBMs) and their discount-based contracts contribute to skyrocketing costs, impacting your wallet and healthcare.

FTC Chair Lina Khan discusses the harmful impact of anti-competitive practices in the PBM industry on CBS This Morning. She highlights the urgent need for greater transparency and the risks of vertical integration.

Uncover the significant price difference between Johnson & Johnson's plan with PBM Express Scripts and SmithRx's cost-effective approach. Find out how our solutions can save on prescription costs.

At this year’s Brown & Brown “Benefits Evolved” event in Dallas, SmithRx Founder and CEO, Jake Frenz, took the stage with Mark Cuban to discuss how brokers can reshape the healthcare landscape. 

The latest PBM Customer Satisfaction Report from the Pharmaceutical Strategies Group (PSG) presents findings that are clear signals of a significant industry shift. 

When it comes to PBM evaluation, explore the importance of choosing a cost-based over discount-based approach to ensure transparency and real savings in prescription medications.

Today we’re excited to share a pivotal milestone in our journey at SmithRx: our $60 Million Series C financing round.

Every American knows that our healthcare system is broken. We all feel the frustration of dealing with the confusing paperwork, archaic systems, and ever-increasing costs. Why is this happening?

2023 was a year about demonstrating true transparency in pharmacy benefits management. It was about nurturing an experience that consistently puts our clients and members first.

In the wake of CVS Health's recent announcement to revamp its drug pricing model, those of us in the pharmacy benefits management world are compelled to examine these changes with a critical eye.

As the SVP of Product Strategy at SmithRx, I've been closely following Cigna’s announcement about their new “cost plus” pharmacy network.

Once Again, the Financial Burden Falls on Employers and Patients

As healthcare costs continue to rise, employers and plan sponsors are continually being pressed to find solutions.

On January 31, 2023, Amgen released Amjevita, the first biosimilar for AbbVie’s Humira.

Big PBMs like OptumRx, Caremark, Prime, and Express Scripts have heard the market demand

The Big 3 PBMs manage thousands of “MAC lists” which enable them to charge different prices for the same drug

Transparency-Rx embraces Congressional reform, as a catalyst of changes to the PBM market

SmithRx, a next-generation pharmacy benefits management company, today announced the closing of a $20 million series B financing round

While drug costs are increasing rapidly, SmithRx’s clients see pharmacy costs fall or remain flat

At SmithRx, we’re all about transparency and passing through savings for prescription drug coverage.

The demand for transparency and affordability in prescription drug pricing has never been more critical.